Coherus Oncology (CHRS) Net Margin (2013 - 2026)
Coherus Oncology (CHRS) posted Net Margin of 11.31% for Q1 2026, down 116.56% sequentially from 68.28% in Q4 2025, and up 10938.0% YoY from N/an in Q1 2025.
Coherus Oncology (CHRS) Net Margin (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Net Margin for 13 years, with the latest figure at 11.31% in Q1 2026.
- Quarterly Net Margin rose 10938.0% year-over-year to 11.31% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 765.58% (up 56039.0% YoY) and the FY2025 annual result came in at 832.66%, down 9160.0% from the prior year.
- Net Margin fell to 11.31% in Q1 2026 per CHRS's latest filing, from 68.28% in the prior quarter.
- Over five years, Net Margin peaked at 7405.16% in Q1 2024 and troughed at 233.47% in Q1 2023.
- A 5-year average of 629.8% and a median of 59.52% in 2024 frame the typical range for Net Margin.
- The sharpest annual moves came in 2024 and 2025: Net Margin surged 763863 bps in 2024, then sank 752584 bps in 2025.
- Over 5 years, Net Margin stood at 129.81% in 2022, then surged by 33 bps to 87.03% in 2023, then soared by 32 bps to 59.52% in 2024, then surged by 215 bps to 68.28% in 2025, then slumped by 117 bps to 11.31% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 11.31%, 68.28%, and 77.66% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 12.74% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -3.12% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -16.51% |
| 10 | Coherus Oncology | 203.82 Mn | 98.51 Mn | 10.07 Mn | -144.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 88.88% |
| Mar 31, 2026 | -11.31% |
| Dec 31, 2025 | 68.28% |
| Sep 30, 2025 | 77.66% |
| Jun 30, 2025 | 3,341.42% |
| Mar 31, 2025 | -120.69% |
| Dec 31, 2024 | -59.52% |
| Sep 30, 2024 | 608.86% |
| Jun 30, 2024 | 407.25% |
| Mar 31, 2024 | 7,405.16% |
| Dec 31, 2023 | -87.03% |
| Sep 30, 2023 | -53.16% |
| Jun 30, 2023 | -73.01% |
| Mar 31, 2023 | -233.47% |
| Dec 31, 2022 | -129.81% |
| Sep 30, 2022 | -190.76% |
| Jun 30, 2022 | -83.37% |
| Mar 31, 2022 | -159.83% |
| Dec 31, 2021 | -62.28% |
| Sep 30, 2021 | -46.70% |